Molina Healthcare (MOH) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Molina Healthcare (NYSE:MOH) is set to announce its Q3 2025 earnings on October 22, 2025, with analysts predicting earnings of $3.82 per share and revenue of $10.9858 billion.
• In the previous quarter, the company reported a revenue increase of 15.7% year-over-year, with earnings per share (EPS) of $5.48, which missed estimates by $0.02.
• Recent ratings from analysts have led to price target reductions, with Barclays setting a target of $185.00 and JPMorgan dropping it to $184.00, reflecting a cautious outlook on the stock.

Molina Healthcare (NYSE:MOH - Get Free Report) is anticipated to announce its Q3 2025 results after the market closes on Wednesday, October 22nd. Analysts expect the company to announce earnings of $3.82 per share and revenue of $10.9858 billion for the quarter. Investors may review the information on the company's upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:00 AM ET.

Molina Healthcare (NYSE:MOH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The company reported $5.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.50 by ($0.02). Molina Healthcare had a net margin of 2.60% and a return on equity of 27.72%. The business had revenue of $11.43 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same period in the previous year, the business posted $5.86 earnings per share. Molina Healthcare's revenue was up 15.7% compared to the same quarter last year. On average, analysts expect Molina Healthcare to post $24 EPS for the current fiscal year and $28 EPS for the next fiscal year.

Molina Healthcare Price Performance

Shares of MOH stock opened at $194.55 on Wednesday. Molina Healthcare has a 52-week low of $151.95 and a 52-week high of $359.97. The stock has a market cap of $10.54 billion, a PE ratio of 9.59 and a beta of 0.55. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.66 and a current ratio of 1.66. The firm's 50 day moving average price is $179.79 and its two-hundred day moving average price is $247.03.

Analyst Upgrades and Downgrades

MOH has been the topic of several recent research reports. Barclays reduced their price target on Molina Healthcare from $186.00 to $185.00 and set an "equal weight" rating on the stock in a research report on Thursday, September 4th. JPMorgan Chase & Co. reduced their target price on Molina Healthcare from $272.00 to $184.00 and set a "neutral" rating on the stock in a report on Tuesday, July 29th. Wall Street Zen cut Molina Healthcare from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Robert W. Baird reduced their target price on Molina Healthcare from $373.00 to $179.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Finally, UBS Group reduced their price objective on shares of Molina Healthcare from $260.00 to $180.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Three analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Molina Healthcare currently has an average rating of "Hold" and a consensus target price of $223.75.

Insider Activity

In related news, COO James Woys purchased 10,000 shares of the business's stock in a transaction on Monday, August 4th. The shares were purchased at an average price of $155.94 per share, with a total value of $1,559,400.00. Following the completion of the purchase, the chief operating officer owned 74,331 shares in the company, valued at $11,591,176.14. This represents a 15.54% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronna Romney sold 700 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $153.74, for a total transaction of $107,618.00. Following the completion of the sale, the director directly owned 17,131 shares in the company, valued at $2,633,719.94. This represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.26% of the company's stock.

Institutional Investors Weigh In On Molina Healthcare

Several institutional investors have recently added to or reduced their stakes in the stock. Baird Financial Group Inc. bought a new stake in shares of Molina Healthcare in the first quarter valued at about $210,000. NewEdge Advisors LLC lifted its stake in Molina Healthcare by 33.4% in the 1st quarter. NewEdge Advisors LLC now owns 1,106 shares of the company's stock valued at $364,000 after acquiring an additional 277 shares in the last quarter. Jones Financial Companies Lllp lifted its stake in Molina Healthcare by 713.3% in the 1st quarter. Jones Financial Companies Lllp now owns 1,651 shares of the company's stock valued at $544,000 after acquiring an additional 1,448 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Molina Healthcare by 19.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 249,466 shares of the company's stock valued at $82,172,000 after acquiring an additional 40,531 shares in the last quarter. Finally, Woodline Partners LP bought a new stake in Molina Healthcare in the 1st quarter valued at approximately $1,541,000. 98.50% of the stock is owned by institutional investors.

Molina Healthcare Company Profile

Molina Healthcare, Inc provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.